Physiologically Based Biopharmaceutics Model of Apixaban for Biopharmaceutics Risk Assessment

<b>Background/Objectives:</b> This study applies a Physiologically Based Biopharmaceutics Modeling (PBBM) framework to predict the bioavailability (BA) and bioequivalence (BE) of apixaban, a borderline BCS Class III/IV drug. It investigates how formulation factors, such as particle size,...

Full description

Bibliographic Details

Published in:	Pharmaceutics
Main Authors:	Paulo Paixão, Zvonimir Petric, José A. G. Morais
Format:	Article
Language:	English
Published:	MDPI AG 2025-03-01
Subjects:	Physiologically Based Biopharmaceutics Modeling apixaban model-informed drug development Critical Biopharmaceutics Attributes
Online Access:	https://www.mdpi.com/1999-4923/17/3/382